🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
MRNA
NASDAQ
🇺🇸 US
Moderna, Inc.
Pharmaceuticals
16Score
DipBuster Score™
$63.96
+$2.16 (+0%)
Live price · Source: FMP-live
52-Week Position
$22.28
92% of range
$67.74
Beta
1.03
Market-like
Dividend
—
no income
Mkt Cap
$25.38B
total value
Mkt Cap$25.38B
P/EN/A
DividendNone
Beta1.03
52W High$67.74
52W Low$22.28
🤖
Not a Dip — Score 16/100
Zone: Sell / Avoid
🔒 Unlock Pro
Valuation
P/E Ratio—
Mkt Cap$25.38B
52W Position92% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta1.03
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️
Insider Buys
Track director & CEO open-market purchases
📊
Valuation Analysis
P/E, EV/EBITDA, DCF & NCAV metrics
📈
Financial Charts
Revenue, EBITDA, FCF & balance sheet trends
🤖
AI Analysis
Plain-English explanation of every key metric
Sign up free — charts & fundamentals included
Get financial charts, valuation data, dividends & news for Moderna, Inc. free. Upgrade to Pro for insider signals & AI analysis.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
3/25
Momentum & Volume
8/25
Quality & Size
5/10
Insider Activity
0/10
Quick Take
⚪
Not a Dip
DipBuster Score: 16/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts targ…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Stéphane Bancel
Staff
5,800 employees
Website